Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 11/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
| ▸ | SLC5A1 | P13866 | 7/20 | 0.43 |
| ▸ | AGXT | P21549 | 1/20 | 0.42 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2873192 | 0.82 | SLC5A2 (0.49) | SLC5A2CYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL12782043 | 0.82 | CYP2A6 (0.53) | SLC5A2CYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL158148 | 0.81 | SLC5A2 (0.53) | SLC5A2CYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL13748566 | 0.81 | SLC5A2 (0.53) | SLC5A2CYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL14278454 | 0.81 | SLC5A2 (0.53) | SLC5A2CYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL14562916 | 0.75 | SLC5A2 (0.53) | SLC5A2CYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL6968526 | 0.75 | NR1D1 (0.53) | SLC5A2CYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL2863591 | 0.74 | CTRC (0.50) | CYP2A6SLC6A3 | |
| SCHEMBL1522855 | 0.74 | CYP2A6 (0.64) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL4961407 | 0.74 | CYP2A6 (0.69) | SLC5A2CYP2A6ADRB2ASIC3LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691898-B2 | Phosphonic acid derivatives and the treating agents of diseases related hyperphosphatemia | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20080119441-A1 | Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| CN-101072783-A | Phosphonic acid derivative and therapeutic agent for disease in which high phosphate level in blood participates | KOTOBUKI PHARMACEUTICAL CO LTD (JP) | 2007-11-14 | — | — | CN | disclosed |
| EP-1813620-A1 | PHOSPHONIC ACID DERIVATIVE AND THERAPEUTIC AGENT FOR DISEASE IN WHICH HIGH PHOSPHATE LEVEL IN BLOOD PARTICIPATES | Kotobuki Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119441-A1 | Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia | NR0B1, NR0B2, PTH1R | SLC5A2 1771/4885CYP2A6 908/4885ADRB2 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.